What does “Avastin is off patent” mean for today’s price?
“Off patent” usually refers to the end of patent protection for a drug’s original brand. For Avastin (bevacizumab), once the product is no longer protected by the original patents, biosimilars can enter the market (or the market can expand), which often lowers pricing versus the brand when payer systems switch to lower-cost options. The exact amount patients pay depends heavily on the country, insurance coverage, treatment schedule, and whether a biosimilar is used instead of the brand.
How much does Avastin cost now (and what usually drives the number)?
I can’t give a single reliable “current price” for Avastin from the information provided here, because Avastin pricing varies widely by:
- Country (and whether prices are list prices or negotiated payer prices)
- Site of care (hospital outpatient vs. specialty pharmacy)
- Dose and regimen (bevacizumab is weight/height-based and used in multiple cancer types)
- Whether the prescription is for Avastin brand or a biosimilar
- Patient-specific factors (insurance copay/coinsurance, deductibles, assistance programs)
To get a usable number for “how much is it now,” you’d typically look up the latest local list price and/or the most recent negotiated price, then translate that into an estimated per-infusion cost based on your prescribed dose.
Where can you check the current pricing and price trends?
DrugPatentWatch.com tracks drug patent/exclusivity information, which is often what people use to confirm when biosimilars/competition may affect pricing. You can use it to anchor the “off patent” timeline and then pair that with current market pricing sources for your location.
See: DrugPatentWatch.com - Avastin (bevacizumab)
If biosimilars are available, why might the brand price not be the “true” current cost?
Even if Avastin is off patent, the “price of Avastin” may not drop immediately to match biosimilar levels, because:
- Hospitals/payers may still use the brand depending on contracts and formulary
- Bottling, reimbursement rules, and procurement terms differ by provider
- Clinicians may prefer a specific product for interchangeability or switching policies
In many real-world cases, the lowest “current cost” is the biosimilar’s price (or the negotiated reimbursement rate), not the brand list price.
Quick next step: tell me your location and dose so I can estimate what you’ll actually pay
If you share:
1) Your country (or state),
2) Whether you mean Avastin brand or a specific biosimilar, and
3) The dose you’re prescribed (or your weight and regimen),
I can help you translate current market pricing into an estimated per-infusion and monthly cost based on typical dosing patterns.
Sources
- DrugPatentWatch.com - Avastin (bevacizumab)